NEWS
-
2023/11/24 Correctseq
CorrectSequence Therapeutics (Correctseq), a biotechnology company using innovative base editing technology to help people with severe disease, today announced that the company and the research teams from ShanghaiTech University, Wuhan University, Fudan University and Children's Hospital of Fudan University published an article entitled “Base editing of the HBG promoter induces potent fetal hemoglobin expression with no detectable off-target mutations in human HSCs” in Cell Stem Cell on November 20th, 2023, reporting a novel base editing strategy for treating β-hemoglobinopathies with transformer base editor (tBE).
-
2023/10/17 Correctseq
CorrectSequence Therapeutics to Participate in the 18th ASCAT Conference
CorrectSequence Therapeutics (Correctseq), a biotechnology company using innovative base editing technology to help people with severe disease, today announced that Dr. Susan Mou, CEO of Correctseq and Dr. Lijie Wang, head of Gene Editing Platform of Correctseq, will attend the 18th Academy for Sickle Cell and Thalassaemia Conference (ASCAT) at the County Hall London, UK on October 25-28, 2023. Dr. Lijie Wang, will give an oral presentation on Oct. 28, at 9:00 am - 11:15 am, local time.
-
2023/10/12 Correctseq
Nature Reviews Molecular Cell Biology：Base editing of organellar DNA with programmable deaminases
Recently, Prof. Jia Chen from ShanghaiTech University and Prof. Jin-Soo Kim from National University of Singapore published a review entitled Base editing of organellar DNA with programmable deaminases in Nature Reviews Molecular Cell Biology.
-
2023/10/06 Correctseq
Nature Protocols：Design and Application of the transformer Base Editor in Mammalian Cells and Mice
Prof. Jia Chen's research team and Prof. Jianfeng Li's research team at ShanghaiTech University, and Prof. Li Yang's research team at the Center for Molecular Medicine, Children’s Hospital, Fudan University jointly published a protocol paper in Nature Protocols, entitled Design and application of the transformer base editor in mammalian cells and mice. The paper describes the working principle, design scheme, and in vivo editing by the tBE.
-
2023/06/01 Correctseq
Correctseq and Thalassemia Children Celebrate the Children's Day
Today is the 73rd’s Children’s Day. On May 31, 2023, the Wuzhishan Branch of Jiusan Society, the branch of Hainan Women and Children's Medical Center and the Wuzhishan Disabled Persons' Federation co-sponsored the "Care for the Children, Walk with the Children" donation activity for exceptional children and thalassemia children to celebrate the Children’s Day, which was held in Wuzhishan Special Education School.
-
2023/01/11 PHARMCUBE Colum
As one of the most important technologies in the field of life science in the 21st century, gene editing technology is gradually showing its application potential and vigorous development. According to the data, the global genome editing market is expected to reach $4.3 billion in 2022 and $12.8 billion in 2027. The global genome editing market is expected to grow at a compound annual growth rate of 24.7% in 2022-2027.
-
2022/12/30 Correctseq
transformer Base Editor of Correctseq Wins the 19th People's Ingenuity Award
The 2022 People's Financial Summit Forum, hosted by www.people.cn online, was held in Beijing on Dec 29. The winners of the 19th People's Ingenuity Award were officially released at the forum. transformer Base Editor (tBE), which is developed by the scientific co-founders of CorrectSequence Therapeutics (Correctseq), won the Ingenuity Award for its higher editing efficiency and better safety in the whole genome and whole transcriptome, and promising to completely cure single base genetic diseases. Correctseq also became the only biotech pharmaceutical company to receive this award.
-
2022/12/17 Correctseq
Oriental Financial Pudong Channel Dialogue 22 Interview with Dr. Xiaodun Mou, CEO of Correctseq
Recently, Dr. Xiaodun Mou, CEO of CorrectSequence Therapeutics, visited the "Dialogue 22" column of Oriental Financial Pudong Channel to share how to use creative gene editing technology to develop low-cost and high-quality therapy for people with severe diseases.